MIRVASO® (brimonidine) topical gel, 0.33% is the first and only FDA-approved treatment developed and indicated for persistent (nontransient) facial redness of rosacea. Facial redness is a common symptom of rosacea, a skin condition that affects an estimated 16 million Americans